Tissium

Tissium

Private
ParisHealthcare & Life Scienceshttps://tissium.com

Last Round

Series D

May 23, 2023

Total Funding Raised

$200.52M

Momentum Score

50 /100

Company Overview

Tissium is a medical device company that develops a platform of biomorphic programmable polymers for tissue reconstruction.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Advanced Materials, 3D Printing, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

biomorphic polymerstissue reconstructionsutureless repairsurgical adhesivessurgical glueperipheral nerve repairprogrammable polymersbioresorbable polymeratraumatic repairlight-activated polymermedtechbiopolymer platformsurgical sealantshernia repair3D printed medical devicenerve coaptationcardiovascular sealants

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tissium Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Tissium Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series DMay 23, 2023
Series CAug 31, 2021
Series BNov 20, 2019
GrantJan 24, 2018
Series A ExtensionMar 17, 2016
Debt
Jan 20, 2015

Key People

Founding team and executive leadership

Christophe Bancel

Founder CEO

Founding Team

Romain Attard

Chief Financial Officer

Executive Team

Tissium Investors

Notable investors and investment history

InvestorRounds
CapDecisif ManagementSeries A Extension, Series B, Series A
BpifranceGrant, Series A Extension, Series B, Debt
ISALTSeries D
European Investment FundSeries B
Crédit Mutuel InnovationSeries D
Fonds Stratégique des TransitionsSeries D
Sofinnova PartnersSeries C, Series B, Series D, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 18, 2026

    Tissium is actively exploring the expansion of its TISSIUM platform into new applications, including nerve repair.

  • Feb 14, 2026

    Preparing for EU launch of hernia product ECLIPSIUM.

Tissium Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tissium Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tissium's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range140
Year Founded2013
Last FundingMay 23, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.